Endocrine Abstracts

Hypothalamic neuropeptides as biomarkers for water-electrolyte disturbances. Introduction Diabetes insipidus is a rare condition characterized by excretion of large amounts of dilute urine and increased thirst. Nephrogenic diabetes insipidus (NDI) is caused by the inability of the kidneys to concentrate urine in response to vasopressin.Aim: The aim of our case report is to present the patient with NDI and to report the data on physiological changes in hy...

Introduction: Diabetes insipidus (DI) is a rare condition characterized by excretion of large amounts of dilute urine and increased thirst due to deficiency or renal resistance of antidiuretic hormone (ADH). DI is often difficult to diagnose reliably and accurately, especially in patients with partial DI.Aim: The aim of our case report is to present the patient with partial diabetes insipidus and to report the results of water deprivation and hypertonic ...

Introduction: Approximately 20% of patients with prolactinomas do not respond satisfactory (resistant) even to high dose dopamine agonist treatment. Worth noticing that there are no clear prognostic signs of treatment’s resistance as well as its etiology is a subject of discussion. Aim: The aim of our study was to assessabsorption and metabolism of cabergoline in patients with dopamine agonist-resistant prolactinomas.Materials...

Background: Acromegaly is an orphan neuroendocrine disease characterized by a variety of complications. Due to slow symptom progression acromegalic patients often are involved in growth hormone complications correction for a long time instead of search for main cause of these multiple disorders. A view on conductive hearing loss in acromegaly in literature is contradictory. The low incidence of hearing in acromegaly, compared with other complications, is presumably due to the ...

Introduction: Prolactinomas are the most common type of pituitary adenomas(40% of them), representing a significant cause of infertility and hypogonadism. About 20% of patients with prolactinomas don’t respond satisfactory(i.e. resistant) even to high dose dopamine agonist(DA) treatment(>3.5–4.5 mg/week). Worth noticing that there are no clear signs to anticipate this resistance but to stepwise increase the dose of DA. In addition, the etiology of resistance &#15...